RECENT NEWS

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, has announced it has been awarded a share of the £3 million Collaborative Discovery Programme (CDP) launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with funding from the medical research charity, LifeArc.

Beckman Coulter Life Sciences and the Indiana University School of Medicine have been awarded a prestigious grant from the National Cancer Institute totalling $2.5 million over a five-year period to increase critical leukaemia and lymphoma testing access in Western Kenya.

The government has confirmed funding and a realistic timetable to put the New Hospital Programme on track to deliver all of its hospital projects. The new timeline for delivery will ensure that staff and patients have access to the facilities they desperately need around the country as soon as possible.

​Arab Health, the Middle East’s largest and most important healthcare event and congress, will return to the Dubai World Trade Centre (DWTC) from 27-30 January 2025. The show will attract an international audience under the theme of ‘Where the world of healthcare meets.'

The National Institute for Health and Care Research (NIHR) has awarded £49.2 million to Cambridge University Hospitals NHS Foundation Trust to continue hosting the NIHR BioResource for four years from 1 April 2025.

The UK government has announced £5.5 million for research into transmission, new vaccines and treatments to tackle the mpox outbreak in the Democratic Republic of Congo and neighbouring countries.

The Microbiology Society has announced that the ‘Hot Topic’ presentation at its Annual Conference 2025 will be ‘Soil Microbiomes and One Health’, given by Professor Marcel van der Heijden.

Hundreds of people with Jewish ancestry in England have been identified as at increased risk of cancer and offered risk-reducing options, as part of a new NHS genetic testing programme.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published new guidance for medical device manufacturers ahead of the new Post-market surveillance (PMS) regulation for medical devices in Great Britain (GB) which will come into force this summer.

Researchers at the University of Oxford have unveiled a new blood test – powered by machine learning – which shows real promise in detecting multiple types of cancer in their earliest stages, when the disease is hardest to detect.

Aignostics has announced research results for a new pathology foundation model developed in collaboration with Mayo Clinic Digital Pathology. The model, built in two months using 1.2 million diverse slide images from Mayo Clinic and Charité – Universitätsmedizin Berlin, establishes a new state-of-the-art for performance across more than twenty public benchmarks.

Revvity has announced a strategic agreement to commercialise an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, a life science company democratising access to advanced DNA and multi-omic sequencing solutions.

AI-enabled pathology solutions company Proscia more than doubled its growth in 2024, it has announced. The company enters 2025 having cemented its leadership position, with life sciences organisations and diagnostic laboratories increasingly deploying its Concentriq enterprise pathology platform to advance the next novel therapies and diagnostics.

Biofidelity, a leader in innovative genomic solutions, and contract research organisation CellCarta, have announced a strategic partnership agreement to utilise Biofidelity’s Aspyre Lung in global clinical trials.

South West London Pathology (SWLP) has celebrated the installation of new cutting-edge technology from Beckman Coulter at its Essential Services Laboratory at Croydon Hospital, creating one of the most modern, innovative, and efficient clinical blood science services in the country.

The Institute of Biomedical Science (IBMS) has published a response to the government’s newly published ‘Reforming elective care for patients’, saying that investing in diagnostic capacity, digital transformation, and a robust biomedical science workforce is essential to delivering faster, more equitable elective care for all.

Next generation testing, artificial intelligence, advanced mass spectrometry and machine learning will be used to bring new diagnostics to NHS patients, thanks to a new partnership between University College London Hospitals NHS Foundation Trust (UCLH) and Guilford Street Laboratories (GSL).

Leica Biosystems has agreed to make a significant strategic investment in Indica Labs, the two pathology firms have announced. This partnership aims to accelerate AI-enabled companion diagnostics and will also create a new digital pathology platform.

Risks that can lead to errors in cancer diagnoses could be reduced, as just one benefit of high precision platelet counting technology, launched by international health technology company Mindray.

Diagnostics firm Geneoscopy has announced new funding of $105 million, led by Bio-Rad Laboratories, to support the launch of non-invasive colorectal cancer screening test ColoSense, and advance diagnostic innovations for inflammatory bowel disease.